Fulminant hepatitis is a severe complication of hepatitis A virus infection. Its mechanism is unknown. Liver transplantation can be necessary, but spontaneous recovery is frequent. There are no data on the level of viral replication according to the clinical form of hepatitis A. We reviewed the files of 50 patients with acute hepatitis A. Nineteen patients had fulminant hepatitis (defined by encephalopathy and factor V <50%), and, from them, 10 patients underwent transplantation. Hepatitis A virus (HAV) RNA was quantified by real-time PCR on sera obtained at admission. The genotype was determined by phylogenetic analysis of HAV RNA. HAV RNA was detected in serum by RT-PCR in 39 out of 50 patients. Encephalopathy and low factor V level were significantly related to female gender, HAV PCR negativity (9/19 vs. 5/31, respectively; P ‫؍‬ .03), a low serum HAV RNA level (log, 3.6 ؎ 0.6 vs. 4.4 ؎ 0.9, respectively; P ‫؍‬ .02), genotypes other than IA, and acetaminophen intake. In multivariate analysis, low or undetectable HAV viral load and a high bilirubin level were independently associated with both low factor V levels and fulminant hepatitis and also with death or transplantation. In conclusion, HAV-related liver failure is due to an excessive host response associated with a marked reduction in viral load. The infection is spread chiefly by fecal-oral transmission and is a public health problem throughout the world. The main complication of HAV infection is fulminant hepatitis (FH), i.e., acute liver failure with encephalopathy, which occurs in less than 1% of cases. It appears to be more frequent in adults than in children. 1 In the United States, about one third of adults have anti-HAV antibodies, and 100 deaths per year are attributed to HAV-related acute liver failure. 1 This is also a frequent cause of death among children in developing countries. 2 Liver transplantation has markedly changed the prognosis of HAV-related acute liver failure in industrialized countries 3 and is currently indicated for patients with deep coma and low factor V levels. However, HAV-related FH resolves spontaneously more frequently than FH of other origins, and the decision to transplant or not to transplant is thus particularly difficult. Auxiliary liver transplantation may be appropriate in this setting, pending possible regeneration of the native liver. 4, 5 Few data have been published on viral replication during acute hepatitis A, and viral load in patients with FH A has not yet been studied. There are several HAV genotypes, IA being most prevalent in industrialized countries. 6 Little information is available on the possible relation between the severity of hepatitis A and the infecting genotype. We applied real-time quantitative polymerase chain reaction (PCR) to stored sera from 50 patients with acute hepatitis A, of whom 19 had FH, to examine the possible relation between HAV viral load, HAV genotype, and the clinical course.
HAV-related acute liver failure. 1 This is also a frequent cause of death among children in developing countries. 2 Liver transplantation has markedly changed the prognosis of HAV-related acute liver failure in industrialized countries 3 and is currently indicated for patients with deep coma and low factor V levels. However, HAV-related FH resolves spontaneously more frequently than FH of other origins, and the decision to transplant or not to transplant is thus particularly difficult. Auxiliary liver transplantation may be appropriate in this setting, pending possible regeneration of the native liver. 4, 5 Few data have been published on viral replication during acute hepatitis A, and viral load in patients with FH A has not yet been studied. There are several HAV genotypes, IA being most prevalent in industrialized countries. 6 Little information is available on the possible relation between the severity of hepatitis A and the infecting genotype. We applied real-time quantitative polymerase chain reaction (PCR) to stored sera from 50 patients with acute hepatitis A, of whom 19 had FH, to examine the possible relation between HAV viral load, HAV genotype, and the clinical course.
A, as defined by the presence of anti-HAV immunoglobulin M (IgM) antibodies. Serum samples obtained from 50 of these patients within 24 hours following their admission were stored at Ϫ20°C and thawed once for the present study. All the patients were symptomatic and were referred for acute jaundice and fatigue. Thirty-one patients were men, and the mean age was 33 years (Ϯ11; range, 16-63 years). Aminotransferase activity peaked between 3 days before admission and 4 days after admission. Nineteen patients were considered as having FH A: acute liver failure with less than 8 weeks between illness onset and encephalopathy (Table 1) . Signs of encephalopathy were present at admission (n ϭ 10) or appeared during the week following admission (n ϭ 9). Of these, 11 patients became comatose within 2 days following admission, with a factor V level less than 50% of normal. Ten patients in coma (encephalopathy grade Ն3) underwent emergency orthotopic liver transplantation, and another patient in deep coma died before a donor liver could be found. All explanted native livers showed more than 80% of hepatocyte necrosis and no signs of other chronic liver diseases. Hepatitis A did not recur during follow-up in any of these 10 patients. The other 39 patients recovered spontaneously, with a marked fall in alanine aminotransferase (ALT) activity and clotting factor normalization within 2 weeks following admission. Two of these patients had a further episode of jaundice, without liver failure, within 3 months following admission. The duration of the HAV incubation period could be estimated in 8 patients (16%) and was not taken into account in this study. Forty patients were known to have taken medications before hepatitis onset. Nineteen (48%) of these patients had taken acetaminophen (less than 3 g/d for less than 3 days) within the 2 weeks preceding admission. Serologic Markers. All the patients tested positive for anti-HAV IgM (Biomerieux, Marcy l'Etoile, France) and negative for other markers of acute infection, namely hepatitis B surface antigen (DiaSorin, Saluggia, Italy), antiHBc IgM (Biomerieux), anti-HEV IgM (Abbott Diagnostics, Chicago, IL), anti-VCA (EBV) IgM (DiaSorin), and anti-CMV IgM and anti-HSV IgM (Dade Behring, Marburg, Germany). All the patients also tested negative for anti-HCV (Ortho diagnostics, Raritan, NJ) and anti-HIV antibodies (Biorad, Marnes la Coquette, France and Behring). Nine patients had serologic evidence of past hepatitis B virus infection (anti-HBc positivity, Biorad).
RNA Extraction and Amplification. Viral RNA was extracted from 140 L of serum by using the QIAmp Viral RNA kit (Qiagen GmbH). HAV genotypes were determined by phylogenetic analysis of the VP1/2A junction region (168 nucleotides). Ten microliters of extracted RNA was subjected to reverse transcription and nested PCR amplification with Ready-to-Go reverse transcription polymerase chain reaction (RT-PCR) and PCR beads (Amersham Pharmacia Biotech, Uppsala, Sweden) and previously described primers. 6 HAV RNA was quantified by using a real-time RT-PCR assay based on Taq Man chemistry. One-step RT-PCR was carried out in a LightCycler instrument (Roche Diagnostics), using the LightCycler RNA amplification kit according to the manufacturer's instructions. The set of primers and probe, derived from the 5Ј noncoding region, consisted of a forward primer (nt 22 to 39) 5Ј-TTTCCGGAGCCCCTCTTG-3, a reverse primer (nt 107 to 85) 5Ј-AAAGGGAAATTTAGCCTATAGCC-3Ј, and a TaqMan probe (nt 58 to 83) 5Ј-FAM-ACTT-GATACCTCACCGCCGTTTGCCT-TAMRA-3Ј. 7 Twenty microliters of the reaction mixture was added to PCR tubes containing 5 L of RNA isolated from serum. HAV RNA was reverse transcribed into cDNA (40 minutes at 45°C), and the 77-bp fragment was amplified by PCR (15 seconds at 94°C and 1 minute at 60°C) for 45 cycles. Ten-fold dilutions of a formaldehyde-inactivated human HAV standard at 10 7 TCID 50 /mL (Sorin Biomedica) were used to construct the standard quantification curve. Statistical Methods. Biologic and virologic parameters recorded within 24 hours following admission were analyzed. The only clinical parameter taken into account was the onset of encephalopathy, as a diagnostic sign of FH. HAV RNA positivity and log 10 serum HAV RNA levels were analyzed according to the following parameters: age; gender; signs of encephalopathy; acetaminophen intake before the admission; and factor V, prothrombin, bilirubin, albumin, and aminotransferase levels. The route of infection, sexual practices, race, epidemic context, and alcohol intake were recorded in too few cases to be analyzed. Univariate and multivariate analyses were performed with StatView software (Abacus concept, Berkeley, CA). Fisher exact test was used to compare 2 nominal variables, and a t test was used for nominal and continuous variables. Logistic regression and multiple regression were used for multivariate analysis of dependent variables (nominal, such as FH and spontaneous recovery of the liver; and continuous, such as the level of factor V and the prothrombin time).
Results

Detection and Quantification of Serum HAV RNA.
In repeated experiments on serial dilutions of the HAV standard, quantitation was found to be linear between 10 2 and 10 7 copies/mL, and values Ն100 copies/mL were taken into account for the analysis of viral loads (Fig. 1) . Serum HAV RNA levels were above 100 copies/mL in 36 of 50 patients (72%): mean viral load 4.1 log copies/mL (Ϯ0.9; range, 2.89-6.39). VP1/2A PCR was positive in 36 of 50 cases (72%). One of these 36 patients with viremia Ͻ100 copies/mL was positive for VP1/2A PCR, whereas another patient with viremia ϭ 1,000 copies/mL was negative. Phylogenetic analyses of VP1/2A sequences included prototypic strains of genotypes I to VII. 6 Eighteen patients clustered with the genotype IA prototype (50%), 12 with IB (33%), 4 with III (11%), and 2 with VII (6%).
Variables Correlating With FH. At admission, patients with FH had higher levels of bilirubin (288 Ϯ 185 mol/L vs. 143 Ϯ 125 mol/L, respectively; P ϭ .004), were more frequently women (12/19 vs. 7/31, respectively; P ϭ .006), and were older (37 Ϯ 13 years vs. 30 Ϯ 9 years, respectively; P ϭ .03) than patients without encephalopathy. HAV PCR was more frequently negative in encephalopathic patients (9/19 vs. 5/31, respectively; P Ͻ .02). Serum HAV RNA levels (when Ն100 copies/mL) were lower in encephalopathic patients (log, 3.6 Ϯ 0.6 vs. 4.4 Ϯ 0.9, respectively; P ϭ .02). Among the 36 patients in whom VP1/2A PCR products were sequenced, 11 of 13 encephalopathic patients FH had genotypes other than IA (genotype IB: n ϭ 8, genotype IIIA: n ϭ 2, genotype VII: n ϭ 1), whereas 7 of 23 patients without encephalopathy had genotypes other than IA (genotype IB: n ϭ 4, genotype IIIA: n ϭ 2, genotype VII: n ϭ 1) (P ϭ .002). In the 40 patients in whom drug intake prior to admission was precisely documented, those with encephalopathy were more likely than those without to have taken acetaminophen (8/10 vs. 11/30, respectively; P ϭ .07) ( Table 2 ). In multivariate analysis (logistic regres- sion), the only independent variables associated with encephalopathy were low or undetectable HAV viral load and a high bilirubin level at admission (Table 3) .
Variables Correlating With Death and Transplantation. Eleven patients did not recover spontaneously: Ten of these patients were grafted, and 1 died before a donor liver was found. Four of these 11 patients had viremia Ͼ100 copies/mL at admission, whereas 32 of the other 39 patients had viremia Ͼ100 copies/mL (P ϭ .02). Seven (63%) of these 11 patients were women, compared with 12 (30%) of the 39 patients who recovered spontaneously (P ϭ .07). Lack of spontaneous recovery was positively related to the bilirubin level (383 Ϯ 182 mol/L vs. 145 Ϯ 112 mol/L, respectively; P ϭ .001). In multivariate analysis, a high bilirubin level and low viremia were significantly related to the risk of death or transplantation (Table 4) .
Variables Correlating With Factor V Levels. In univariate analysis, the factor V level was higher in men than in women (71% Ϯ 30% vs. 47.6% Ϯ 29.5%, respectively; P ϭ .009). It was also higher in patients with viremia Ͼ100 copies/mL (68% Ϯ 29% vs. 36% Ϯ 32%, respectively; P ϭ .005) and those with genotype 1A infection (79% Ϯ22% vs. 43% Ϯ26%, respectively; P ϭ .001). Among the 36 patients with viremia Ն100 copies/ mL, the factor V level correlated positively with HAV viral load (coefficient, 12; CI: 2.1, 21; P ϭ .01). The factor V level correlated negatively with the bilirubin level (coefficient, Ϫ1.02; CI: Ϫ1.98, Ϫ0.05; P ϭ .01). In multivariate analysis (multiple regression), the only variable that correlated with the factor V level was viral load (coefficient, 5.6; CI: 1.4, 9.9; P ϭ .01) (Fig. 2) . Similar results were obtained when the prothrombin time was the independent variable (data not shown).
In all these analysis, variables such as the usual place of residence (France or elsewhere), the serum storage time before HAV RNA assay, and transaminase and albumin levels did not correlate either with the dependent variables analyzed (encephalopathy, absence of liver recovery, and factor V level) or with the other independent variables included in the analysis.
Discussion
Low viral load was the main factor associated with FH A in this series of 50 patients. Viral load also correlated positively with the factor V level. These independent links suggest that HAV replication efficiency and hepatocyte injury be dissociated, at least in patients with severe hepatitis A. In the 10 explanted livers, a massive hepatocyte necrosis was observed, whereas the viral load at admission was either undetectable (6/10 cases) or low (4/10 cases). A similar situation has been described in FH B. 8 As with most other known hepatitis viruses, HAV-induced liver disease appears to result primarily from immunologic mechanisms, chiefly on the basis of in vitro studies. Most HAV strains have no detectable cytopathic effect in cell culture and no apparent effect on cell growth or metabolism. 9 In addition, HAV-infected cells are lysed by cytotoxic T cells isolated from the liver of acutely infected patients. 10, 11 In patients with HIV-associated immunodeficiency, the rise in aminotransferase levels is lower, and HAV-related acute liver failure has not been reported despite increased viral loads and prolonged viremia. 12 However, an obvious limitation to the hypothesis of fulminant HAV infection as an immunologic process is the absence of histologic data for the patients with spontaneous resolution. Anti-HAV IgM emerges concomitantly with symptoms, and viremia is detected by qualitative PCR 2 weeks before the ALT peak and for several weeks after symptom onset. [13] [14] [15] Fujiwara et al. reported a correlation between ALT levels and HAV RNA positivity. 14 In these previous studies, serum HAV RNA was mainly analyzed during mild hepatitis, and no correlation was sought between markers of disease severity and viral load. Here, we compared 19 patients with encephalopathy and 31 patients with a milder course. Viremia was quantified in all our patients at admission, corresponding to the week during which the aminotransferase peak occurred. A recent longitudinal study based on semiquantitative assessment of serum HAV RNA showed that maximum viremia precedes the ALT peak by 1 to 3 weeks and that viremia measured at ALT peak was of 3 to 4 log copies/mL, 15 a value confirmed here by quantitative RT-PCR (mean, 4.1 log).
Although wild-type HAV has a characteristically slow and noncytopathic replication cycle in cell culture, several cytopathic variants have been described. Cytopathic effects and cell-culture adaptation are associated with various mutations distributed throughout the 5Ј noncoding region and the nonstructural genomic regions. [16] [17] [18] [19] [20] Furthermore, adaptation of HAV toward efficient replication in cell culture can result in a loss of virulence in humans and other primates, 21 indicating common genetic determinants of these 2 biologic properties and suggesting that viral factors might be involved in determining the severity of the disease. Recently, a study of 3 familial cases of FH A suggested that some strains of HAV might be particularly pathogenic. 22 HAV strains isolated to date have been divided into 7 genotypes based on the criterion of 15% to 20% nucleotide sequence diversity over a 168-base segment at the VP1/2A junction. In our series, patients infected by genotype IA strains (which predominate in France) had a lower incidence of FH, but the difference was not significant in multivariate analysis. A Japanese study of 27 patients suggested that mutations in the 5Ј noncoding region corresponding to the internal ribosome entry site could increase the severity of HAV liver disease. 23 The same authors confirmed this by analyzing fulllength HAV sequences from 6 patients (3 with benign hepatitis and 3 with FH), all belonging to HAV genotype IA, 24 suggesting that the HAV genotype may not be the main determinant of clinical severity.
It was previously considered that HAV disease severity was linked to individual host factors such as age and underlying liver disease. Increasing age is classically related to increased HAV morbidity and mortality, but it is not clear whether this is due directly to liver failure or rather to decompensation of underlying diseases. 25 None of our patients were coinfected by HCV, as previously described in Italian patients, 26 and, although aging appeared to be linked to increased severity, age did not emerge as an independent factor in multivariate analysis. The relation observed here between male gender and favorable outcome has not previously been reported and may have been due to the fact that genotype IA strains were more frequent both in men (data not shown) and in patients with a favorable outcome. Finally, acetaminophen intake was significantly related to the risk of encephalopathy in univariate analysis and also to high ALT and bilirubin levels (data not shown). Acetaminophen intake, including in patients with FH, was low and not sufficient to cause per se a significant hepatotoxicity. No renal failure or myelotoxicity was observed in the 19 patients with severe disease. However, the conjunction of hepatotoxic factors may contribute to the severity of the liver disease as suggested in this paper in univariate analysis. N-acetyl cys- teine was given in patients with positive detection of paracetamol.
This series tends to confirm that the severity of hepatitis A is multifactorial, with age, gender, and drug toxicity all playing a role. However, the influence of host factors was lost in multivariate analysis with HAV viral load as the independent variable. This strongly suggests that low viremia is the most important factor associated with liver failure in this setting, presumably owing to a strong immune response. Our findings could thus help to establish the prognosis of such patients. Indeed, a low viral load in an encephalophatic patient could help for the very difficult decision of transplantation, the main therapeutic option for FH A, yet spontaneous recovery is frequent. The recent availability of commercial standardized assays for HAV quantification should prove useful for accurate and rapid measurement of serum HAV RNA and for studying the prognostic significance of viral load in acute HAV infection.
